Xiang Yan Selected Research

Erlotinib Hydrochloride (CP 358,774)

10/2020	GLI1 activation is a key mechanism of erlotinib resistance in human non-small cell lung cancer.
2/2014	Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failure.
1/2014	Fatal interstitial lung disease after addition of sorafenib to a patient with lung adenocarcinoma who had failed to improve with erlotinib alone.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiang Yan Research Topics

Disease

29	Neoplasms (Cancer) 12/2023 - 04/2011
20	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2023 - 01/2014
19	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2024 - 01/2003
14	Type 2 Diabetes Mellitus (MODY) 01/2023 - 01/2003
11	Urinary Bladder Neoplasms (Bladder Cancer) 12/2023 - 12/2004
10	Latent Autoimmune Diabetes in Adults 12/2023 - 01/2003
9	Insulin Resistance 11/2022 - 01/2005
7	Inflammation (Inflammations) 03/2022 - 03/2005
6	Infections 12/2023 - 09/2010
6	Neoplasm Metastasis (Metastasis) 01/2023 - 06/2019
6	Fibrosis (Cirrhosis) 01/2022 - 01/2015
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 06/2010
6	Lung Neoplasms (Lung Cancer) 01/2021 - 03/2012
4	Pain (Aches) 09/2022 - 06/2017
4	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2018
4	Stomach Neoplasms (Stomach Cancer) 06/2019 - 01/2014
3	Wounds and Injuries (Trauma) 01/2024 - 08/2013
3	Hemorrhage 01/2024 - 06/2010
3	Kidney Calculi (Kidney Stone) 03/2023 - 10/2012
3	Body Weight (Weight, Body) 10/2022 - 08/2019
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 12/2003
3	Carcinoma (Carcinomatosis) 03/2021 - 01/2014
3	Obesity 10/2020 - 01/2019
3	Adenocarcinoma 01/2020 - 03/2012
3	Adenocarcinoma of Lung 01/2019 - 01/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 02/2015 - 11/2010
3	Hypertension (High Blood Pressure) 08/2013 - 01/2003
2	Seizures (Absence Seizure) 01/2024 - 02/2022
2	Meningioma (Meningiomas) 01/2024 - 02/2022
2	Urolithiasis 09/2023 - 03/2006
2	Shock 09/2023 - 10/2012
2	Necrosis 08/2023 - 01/2021
2	Bone Resorption 01/2023 - 01/2021
2	Diabetes Mellitus 06/2022 - 01/2022
2	Hypoglycemia (Reactive Hypoglycemia) 06/2022 - 08/2010
2	Liver Neoplasms (Liver Cancer) 01/2022 - 01/2019
2	Diabetes Complications 01/2021 - 11/2003
2	Carcinogenesis 01/2021 - 12/2016
2	Parkinson Disease (Parkinson's Disease) 11/2020 - 01/2019
2	Ureteral Obstruction 11/2019 - 01/2015

Drug/Important Bio-Agent (IBA)

14	Insulin (Novolin)FDA Link 01/2023 - 01/2003
11	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2022 - 01/2003
10	ErbB Receptors (EGF Receptor)IBA 10/2022 - 01/2014
8	AutoantibodiesIBA 01/2023 - 11/2003
6	Immune Checkpoint InhibitorsIBA 02/2023 - 01/2019
6	Blood Glucose (Blood Sugar)IBA 06/2022 - 07/2010
5	Biomarkers (Surrogate Marker)IBA 02/2024 - 01/2020
4	Hemoglobins (Hemoglobin)IBA 01/2023 - 01/2003
4	LipidsIBA 11/2022 - 12/2005
4	dacomitinibIBA 10/2022 - 01/2022
4	Messenger RNA (mRNA)IBA 10/2022 - 12/2016
4	Insulin Glargine (Lantus)FDA Link 06/2022 - 07/2008
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2004
4	Gemcitabine FDA Link 01/2022 - 01/2015
4	AntigensIBA 01/2022 - 06/2012
4	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2014
4	C-PeptideIBA 01/2021 - 01/2003
3	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2019
3	Peptides (Polypeptides)IBA 12/2023 - 01/2018
3	CholesterolIBA 01/2023 - 01/2019
3	Zinc Transporter 8IBA 01/2023 - 10/2010
3	Vitamin D FDA LinkGeneric 01/2023 - 07/2009
3	CollagenIBA 01/2021 - 01/2015
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 10/2020 - 07/2010
3	AntibodiesIBA 10/2020 - 06/2004
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2020 - 01/2014
3	Cisplatin (Platino)FDA LinkGeneric 08/2019 - 08/2015
3	SmokeIBA 01/2017 - 08/2013
2	Saline SolutionIBA 01/2024 - 01/2014
2	Tranexamic Acid (AMCA)FDA Link 01/2024 - 02/2022
2	Albumin-Bound Paclitaxel FDA Link 01/2023 - 01/2017
2	Alkaline PhosphataseIBA 01/2023 - 01/2021
2	OsteocalcinIBA 01/2023 - 01/2021
2	HLA-DR Antigens (HLA-DR)IBA 01/2023 - 01/2022
2	collagen type I trimeric cross-linked peptideIBA 01/2023 - 01/2021
2	Monoclonal AntibodiesIBA 01/2023 - 01/2021
2	Bevacizumab (Avastin)FDA Link 01/2023 - 01/2021
2	Dietary Fiber FDA Link 10/2022 - 01/2020
2	osimertinibIBA 09/2022 - 01/2021
2	icotinibIBA 06/2022 - 02/2014
2	LY2963016 insulin glargineIBA 06/2022 - 10/2021
2	ZincIBA 01/2022 - 10/2010
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2017
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2021 - 01/2014
2	CalciumIBA 01/2021 - 01/2021
2	Hematoxylin (Haematoxylon)IBA 01/2021 - 01/2014
2	Small Interfering RNA (siRNA)IBA 10/2020 - 04/2013
2	Tumor Biomarkers (Tumor Markers)IBA 01/2020 - 10/2018
2	Long Noncoding RNAIBA 01/2020 - 01/2018

Therapy/Procedure

25	Therapeutics 02/2023 - 12/2005
7	Immunotherapy 01/2024 - 03/2012
7	Drug Therapy (Chemotherapy) 01/2023 - 03/2012
5	Length of Stay 12/2023 - 06/2010
5	Nephrectomy 01/2021 - 06/2010
4	Percutaneous Nephrolithotomy 01/2024 - 03/2006
4	Radiofrequency Ablation 07/2016 - 04/2011
4	Ureteroscopes 02/2015 - 03/2006
3	Lithotripsy (Extracorporeal Shockwave Lithotripsy) 09/2023 - 03/2006
3	Cryosurgery 06/2015 - 06/2010
3	Catheters 02/2015 - 11/2010